121 related articles for article (PubMed ID: 38552841)
1. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
Lafayette R; Barbour S; Israni R; Wei X; Eren N; Floege J; Jha V; Kim SG; Maes B; Phoon RKS; Singh H; Tesař V; Lin CJF; Barratt J
Kidney Int; 2024 Jun; 105(6):1306-1315. PubMed ID: 38552841
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH; Barratt J; Heerspink HJL; Alpers CE; Bieler S; Chae DW; Diva UA; Floege J; Gesualdo L; Inrig JK; Kohan DE; Komers R; Kooienga LA; Lafayette R; Maes B; Małecki R; Mercer A; Noronha IL; Oh SW; Peh CA; Praga M; Preciado P; Radhakrishnan J; Rheault MN; Rote WE; Tang SCW; Tesar V; Trachtman H; Trimarchi H; Tumlin JA; Wong MG; Perkovic V;
Lancet; 2023 Dec; 402(10417):2077-2090. PubMed ID: 37931634
[TBL] [Abstract][Full Text] [Related]
3. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Liu LJ; Yang YZ; Shi SF; Bao YF; Yang C; Zhu SN; Sui GL; Chen YQ; Lv JC; Zhang H
Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
Hogg RJ; Bay RC; Jennette JC; Sibley R; Kumar S; Fervenza FC; Appel G; Cattran D; Fischer D; Hurley RM; Cerda J; Carter B; Jung B; Hernandez G; Gipson D; Wyatt RJ
Am J Kidney Dis; 2015 Nov; 66(5):783-91. PubMed ID: 26209543
[TBL] [Abstract][Full Text] [Related]
5. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
6. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL; Radhakrishnan J; Alpers CE; Barratt J; Bieler S; Diva U; Inrig J; Komers R; Mercer A; Noronha IL; Rheault MN; Rote W; Rovin B; Trachtman H; Trimarchi H; Wong MG; Perkovic V;
Lancet; 2023 May; 401(10388):1584-1594. PubMed ID: 37015244
[TBL] [Abstract][Full Text] [Related]
7. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study.
Yu MY; Kim YC; Koo HS; Chin HJ
PLoS One; 2017; 12(11):e0188375. PubMed ID: 29155873
[TBL] [Abstract][Full Text] [Related]
8. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC; Barratt J; Cook H; Coppo R; Feehally J; de Fijter JW; Floege J; Hetzel G; Jardine AG; Locatelli F; Maes BD; Mercer A; Ortiz F; Praga M; Sørensen SS; Tesar V; Del Vecchio L;
Lancet; 2017 May; 389(10084):2117-2127. PubMed ID: 28363480
[TBL] [Abstract][Full Text] [Related]
9. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Kappos L; Hartung HP; Freedman MS; Boyko A; Radü EW; Mikol DD; Lamarine M; Hyvert Y; Freudensprung U; Plitz T; van Beek J;
Lancet Neurol; 2014 Apr; 13(4):353-63. PubMed ID: 24613349
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial.
Barratt J; Liew A; Yeo SC; Fernström A; Barbour SJ; Sperati CJ; Villanueva R; Wu MJ; Wang D; Borodovsky A; Badri P; Yureneva E; Bhan I; Cattran D;
Clin J Am Soc Nephrol; 2024 Apr; 19(4):452-462. PubMed ID: 38214599
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria.
Barratt J; Tumlin J; Suzuki Y; Kao A; Aydemir A; Pudota K; Jin H; Gühring H; Appel G;
Kidney Int Rep; 2022 Aug; 7(8):1831-1841. PubMed ID: 35967104
[TBL] [Abstract][Full Text] [Related]
12. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial.
van Vollenhoven RF; Kinnman N; Vincent E; Wax S; Bathon J
Arthritis Rheum; 2011 Jul; 63(7):1782-92. PubMed ID: 21452294
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.
van Vollenhoven RF; Wax S; Li Y; Tak PP
Arthritis Rheumatol; 2015 Nov; 67(11):2828-36. PubMed ID: 26137975
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.
Merrill JT; Wallace DJ; Wax S; Kao A; Fraser PA; Chang P; Isenberg D;
Arthritis Rheumatol; 2018 Feb; 70(2):266-276. PubMed ID: 29073347
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R; Kristensen J; Stone A; Floege J; Tesař V; Trimarchi H; Zhang H; Eren N; Paliege A; Reich HN; Rovin BH; Barratt J;
Lancet; 2023 Sep; 402(10405):859-870. PubMed ID: 37591292
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
Mathur M; Barratt J; Chacko B; Chan TM; Kooienga L; Oh KH; Sahay M; Suzuki Y; Wong MG; Yarbrough J; Xia J; Pereira BJG;
N Engl J Med; 2024 Jan; 390(1):20-31. PubMed ID: 37916620
[TBL] [Abstract][Full Text] [Related]
17. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial.
Genovese MC; Kinnman N; de La Bourdonnaye G; Pena Rossi C; Tak PP
Arthritis Rheum; 2011 Jul; 63(7):1793-803. PubMed ID: 21452293
[TBL] [Abstract][Full Text] [Related]
18. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J; Lafayette R; Kristensen J; Stone A; Cattran D; Floege J; Tesar V; Trimarchi H; Zhang H; Eren N; Paliege A; Rovin BH;
Kidney Int; 2023 Feb; 103(2):391-402. PubMed ID: 36270561
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy.
Kim YC; Chin HJ; Koo HS; Kim S
PLoS One; 2013; 8(8):e71545. PubMed ID: 23977072
[TBL] [Abstract][Full Text] [Related]
20. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
Li P; Chen YZ; Lin HL; Ni ZH; Zhan YL; Wang R; Yang HT; Fang JA; Wang NS; Li WG; Sun XF; Chen XM
Trials; 2017 Apr; 18(1):170. PubMed ID: 28395659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
